SEC Form 4 · accession 0001395064-26-000268
TAKEDA PHARMACEUTICAL CO LTD · TAK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce D Broussard
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 6:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001395064
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary Shares | Jul 1, 2026 | A | 3,800 | $0.00 | A | 4,595 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tax Obligation AwardF2 | — | Jul 1, 2026 | A | 1,319 | A | Jun 1, 2029 | Jun 1, 2029 | Ordinary Shares | 1,319 | 1,319 | D |
Explanation of responses
- F1Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
- F2Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.